Randomized controlled trials in the era of molecular oncology: Methodology, biomarkers, and end points

Annals of Oncology

Volumn 23, Issue 6, 2012, Pages 1646-1651

  Kay, A ^a,b   Higgins, J ^a   Day, A G ^b   Meyer, R M ^a,b   Booth, C M ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

Biomarkers; Chemotherapy; Clinical trials; End points; Oncology; Outcomes

Indexed keywords

APRINOCARSEN; BEVACIZUMAB; BEXAROTENE; BIOLOGICAL MARKER; CETUXIMAB; DOFEQUIDAR; EDRECOLOMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; GEFITINIB; LAPATINIB; PANITUMUMAB; PRINOMASTAT; PROGESTERONE RECEPTOR; REBIMASTAT; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; COLORECTAL CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; ONCOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84861736627     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr492     Document Type: Article

References (29)

1. Booth CM, Cescon DW, Wang L et al. Evolution of the randomized controlled trial in oncology over three decades. J Clin Oncol 2008; 26(33): 5458-5464.
2. Fraser GAM, Meyer RM. Biomarkers and the design of clinical trials in cancer. Biomark Med 2007; 1(3): 387-397.
3. National Cancer Institute. Biomarker, imaging, and quality of life studies funding program. 2011; http://biqsfp.cancer.gov/eligible/(12 May 2011, date last accessed).
4. Booth CM, Tannock I. Reflections on medical oncology: 25 years of clinical trials-where have we come andwhere arewe going? J Clin Oncol 2008; 26(1): 6-8.
5. Saltz LB. Progress in cancer care: the hope, the hype, and the gap between reality and perception. J Clin Oncol 2008; 26(31): 5020-5021.
6. Meropol NJ, Schrag D, Smith TJ et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 2009; 27(23): 3868-3874.
7. Goldenberg NA, Spyropoulos AC, Halperin JL et al. Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. Blood 2011; 117(7): 2089-2092.
8. Meunier F, Garattini S. Future of independent academic clinical research in Europe. 2010; http://newsletter.eortc.be/?p=1143 (12 May 2011, date last accessed) Belgium, European Organization for Research and Treatment of Cancer (EORTC).
9. DeMets DL, Califf RM. A historical perspective on clinical trials innovation and leadership: where have the academics gone? JAMA 2011; 305(7): 713-714.
10. Nass SJ, Balogh E, Mendelsohn J. A National Cancer Clinical Trials Network: Recommendations From the Institute of Medicine. Am J Ther 2011; 18(5): 382-391.
11. Gill S, Sargent D. End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival? Oncologist 2006; 11(6): 624-629.
12. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8(4): 431-440.
13. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1992; 11(2): 167-178.
14. Buyse M, Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 1998; 54(3): 1014-1029.
15. Begg CB, Leung D. On the use of surrogate end points in randomized trials. J R Stat Soc 2000; 163: 15-28.
16. Soria JC, Massard C, Le CT. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol 2010; 21(12): 2324-2332.
17. Sargent DJ, Wieand HS, Haller DG et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005; 23(34): 8664-8670.
18. Sargent DJ, Patiyil S, Yothers G et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 2007; 25(29): 4569-4574.
19. Buyse M, Burzykowski T, Carroll K et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007; 25(33): 5218-5224.
20. Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007; 25(29): 4562-4568.
21. Ng R, Pond GR, Tang PA et al. Correlation of changes between 2-year diseasefree survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006. Ann Oncol 2008; 19(3): 481-486.
22. Sherrill B, Amonkar M, Wu Y et al. Relationship between effects on time-todisease progression and overall survival in studies of metastatic breast cancer. Br J Cancer 2008; 99(10): 1572-1578.
23. Hackshaw A, Knight A, Barrett-Lee P, Leonard R. Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. Br J Cancer 2005; 93(11): 1215-1221.
24. Burzykowski T, Buyse M, Piccart-Gebhart MJ et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 2008; 26(12): 1987-1992.
25. Miksad RA, Zietemann V, Gothe R et al. Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care 2008; 24(4): 371-383.
26. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357(20): 2040-2048.
27. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359(17): 1757-1765.
28. Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27(12): 2091-2096.
29. Krzyzanowska MK, Pintilie M, Tannock IF. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA 2003; 290(4): 495-501.